TOR1AIP2 and acute myeloid leukemia: Interestingly, the expression level of TOR1AIP2 represented by the FPKM of this patient was higher than those of patients with AML without such chimeric fusion, indicating that it could lead to the onset of AML via the upregulation of the expression of TOR1AIP2, with the ETV6 FPKM value remaining unaffected (Supplementary Figure S1).